RAS as an ‘Undruggable’ Drug Target
Guest post by William G. Nelson, MD, PhDEditor-in-Chief, Cancer Today Mutant HRAS, KRAS, or NRAS genes have been found in...
Category: Uncategorized
Guest post by William G. Nelson, MD, PhDEditor-in-Chief, Cancer Today Mutant HRAS, KRAS, or NRAS genes have been found in...
June 2022 marked the 10th Annual Cancer Immunotherapy Month spearheaded by the Cancer Research Institute. Immunotherapy is an umbrella...
At the age of 40, Marlena Murphy was diagnosed with triple-negative breast cancer, an aggressive subtype that occurs twice...
The American Association for Cancer Research (AACR) is proud to offer Global Scholar-in-Training Awards (GSITA) to support the career...
As we finally welcome spring, enjoy this hand-picked selection of articles brought to you by the editors of the...
For the past three years, cohorts of talented young researchers from around the world have participated in the AACR Annual...
AACR on Campus – Defeating Cancer through Global Education and Training is a global outreach program that will bring...
Guest post by Patrick Tan, MD, PhD From November 1-3, 2021, Singapore will hold its 13th Frontiers in Cancer...
Due to advances in screening and treatment, the survival rate for patients with breast cancer has increased in recent decades. However, this progress...
Once considered undruggable, mutant KRAS has emerged in recent years as a viable target for anticancer therapeutics. As a...